{"id":544889,"date":"2021-05-26T18:14:01","date_gmt":"2021-05-26T18:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544889"},"modified":"2021-05-26T18:14:01","modified_gmt":"2021-05-26T18:14:01","slug":"sickle-cell-disease-scd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sickle-cell-disease-scd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544889.html","title":{"rendered":"Sickle Cell Disease (SCD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Sickle<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cSickle Cell Disease (SCD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Sickle Cell Disease (SCD), historical and forecasted epidemiology as well as the Sickle Cell Disease (SCD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Sickle Cell Disease (SCD) -Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Sickle Cell Disease (SCD)  – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Sickle Cell Disease (SCD), historical and forecasted epidemiology as well as the  Sickle Cell Disease (SCD)  market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    According to the research, it is estimated that SCD affects approximately 100,000 Americans. It occurs among about 1 out of every 365 Black or African-American births, about 1 out of every 16,300 Hispanic-American births, and about 1 in 13 Black or African-American babies is born with sickle cell trait.<\/p>\n<\/li>\n

  2. \n

    According to the institute,“Sickle cell disease is the most common inherited blood disorder in the United States, affecting 70,000 to 80,000 Americans. The disease is estimated to occur in 1 in 500 African Americans and 1 in 1,000 to 1,400 Hispanic Americans.”<\/p>\n<\/li>\n

  3. \n

    As per a study, the global meta-estimate for the birth prevalence of homozygous sickle cell disease was 111.91 per 100 ,000 live births and that for heterozygous sickle cell disease was 4229.72 per 100 ,000, and it was least in Europe, i.e., 803.57 per 100,000 live births.<\/p>\n<\/li>\n

  4. \n

    According to a report, it has been estimated that SCD occurs in approximately 300,000 births annually around the globe.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1.The Sickle Cell Disease (SCD) market report covers a descriptive overview and comprehensive insight of the Sickle Cell Disease (SCD)  epidemiology and Sickle Cell Disease (SCD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2.The Sickle Cell Disease (SCD) market report provides insights on the current and emerging therapies.<\/p>\n

    3.Sickle Cell Disease (SCD) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4.The Sickle Cell Disease (SCD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Sickle Cell Disease (SCD) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/sickle-cell-disease-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Sickle Cell Disease (SCD): Overview<\/strong><\/p>\n

    Sickle cell disease is a group of inherited red blood cell disorders that affects hemoglobin, the protein that carries oxygen through the body. Normally, red blood cells are disc shaped and flexible to move easily through the blood vessels. If you have sickle cell disease, your red blood cells are crescent or “sickle” shaped. These cells do not bend and move easily and can block blood flow to the rest of your body.<\/p>\n

    The blocked blood flow through the body can lead to serious problems, including stroke, eye problems, infections and episodes of pain, called pain crises.<\/p>\n

    The key players involved in the Sickle Cell Disease (SCD) market<\/a>:<\/strong><\/p>\n

      \n
    1. \n

      Pfizer, <\/p>\n<\/li>\n

    2. \n

      AstraZeneca, <\/p>\n<\/li>\n

    3. \n

      Emmaus Life Sciences, Inc.<\/p>\n<\/li>\n

    4. \n

      BlueBird Bio<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the Sickle Cell Disease (SCD) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        Rivipansel<\/p>\n<\/li>\n

      2. \n

        Ticagrelor<\/p>\n<\/li>\n

      3. \n

        Endari<\/p>\n<\/li>\n

      4. \n

        LentiGlobin BB305<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/sickle-cell-disease-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Sickle Cell Disease (SCD) Patient Share (%) Overview at a Glance<\/p>\n

        5. Sickle Cell Disease (SCD) Market Overview at a Glance<\/p>\n

        6. Sickle Cell Disease (SCD) Disease Background and Overview<\/p>\n

        7. Sickle Cell Disease (SCD) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Sickle Cell Disease (SCD) <\/p>\n

        9. Sickle Cell Disease (SCD) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Sickle Cell Disease (SCD) Emerging Therapies<\/p>\n

        12. Sickle Cell Disease (SCD) Market Outlook<\/p>\n

        13. Country-Wise Sickle Cell Disease (SCD) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Sickle Cell Disease (SCD) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Sickle Cell Disease (SCD)- Pipeline Insights, 2021<\/strong><\/p>\n

        “Sickle Cell Disease (SCD)- Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Sickle Cell Disease (SCD) market. A detailed picture of the Sickle Cell Disease (SCD) pipeline landscape is provided, which includes the disease overview and Sickle Cell Disease (SCD) treatment guidelines.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cSickle Cell Disease (SCD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Sickle Cell Disease (SCD), historical and forecasted epidemiology as well as the Sickle Cell Disease (SCD) market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-544889","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544889"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544889\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}